直接抗病毒药物治疗慢性丙型病毒性肝炎的研究现状

发布时间：2018-05-20 17:47

本文选题：丙型病毒性肝炎 + DAA　；参考：《南昌大学》2017年硕士论文

【摘要】：背景:我国是肝病大国,丙型肝炎病毒(Hepatitis C virus,HCV)的感染率一直居高不下,然而公众对于慢性丙型肝炎(Chronic hepatitis C,CHC)的了解一直处于较低的水平。慢性丙型肝炎的起病隐匿及临床症状的不明显,导致HCV感染者诊断和治疗可及性较低。长期慢性的HCV感染会对肝脏功能造成严重的损害,甚至引起肝硬化(liver cirrhosis,LC)、肝细胞癌(Hepatocellular Carcinoma,HCC)和肝功能衰竭。据WHO报道,全球约有1.3亿至1.5亿人受到慢性HCV感染,在未来5-10年间,HCV相关的肝脏疾病仍将会持续增加。传统HCV感染患者治疗方案病毒持续应答率(Sustained virological response,SVR)较低,副作用大,治疗效果差。自2011年直接抗病毒药物(Direct acting antivirals agent,DAA)问世以来,丙型病毒性肝炎治疗取得了飞速发展,同时对于丙型病毒性肝炎直接抗病毒药物各方面的研究也越来越多。目的:通过综述直接抗病毒药物治疗慢性丙型病毒性肝炎的研究现状,从而为临床上治疗丙型病毒性肝炎提供一定的参考。方法:以“丙型病毒性肝炎、DAA、直接抗病毒药物、耐药性、肝硬化”等关键词进行检索,找出丙肝直接抗病毒药物的相关研究并对其分类、治疗效果及安全性等进行总结。结果与结论:近年来有大量关于慢性丙型病毒性肝炎直接抗病毒药物(DAA)研究的文献,综合这些研究结果表明,DAA作为新一代抗HCV病毒药物,具有获得持续病毒学应答率(SVR)高、复发率低、不良反应少等优势,且DAA在HCV相关肝硬化患者的治疗中具有极为广阔的应用前景。但DAA单药治疗HCV感染易产生耐药性,指南[1]推荐不同靶点的药物需同时使用。
[Abstract]:Background: China is a large liver disease country, the infection rate of hepatitis C virus (hepatitis C virus) has been high, but the public understanding of chronic hepatitis C virus (Chronic hepatitis) has been at a low level. The occult onset of chronic hepatitis C and the lack of clinical symptoms lead to the low availability of diagnosis and treatment in patients with HCV. Chronic HCV infection can cause serious damage to liver function, and even lead to liver cirrhosis, hepatocellular carcinoma (HCC) and liver failure. According to the WHO, about 130 million to 150 million people worldwide are infected with chronic HCV, and the number of HCV-related liver diseases will continue to increase in the next five to 10 years. The rate of sustained virological response in patients with traditional HCV infection was low, the side effect was large, and the therapeutic effect was poor. Since the direct antiviral drug Direct acting antivirals agentaday (DAA) came out in 2011, the treatment of viral hepatitis C has made rapid progress. At the same time, there are more and more researches on all aspects of direct antiviral drugs for viral hepatitis C. Objective: to review the research status of direct antiviral drugs in the treatment of chronic hepatitis C, and to provide some references for clinical treatment of viral hepatitis C. Methods: the key words of "DAA, direct antiviral drug, drug resistance, liver cirrhosis" were searched to find out the related research of direct antiviral drugs in hepatitis C and to summarize their classification, therapeutic effect and safety. Results & conclusion: in recent years, there have been a large number of literatures on direct antiviral drugs (DAA) in chronic hepatitis C. synthesizing these results indicate that as a new generation of antiviral drugs, it has a high rate of obtaining persistent virological response. The recurrence rate is low, the adverse reaction is less, and DAA has a broad application prospect in the treatment of HCV related cirrhosis patients. However, DAA monotherapy is susceptible to drug resistance in the treatment of HCV infection, and guidelines [1] recommend that different target drugs should be used at the same time.
【学位授予单位】：南昌大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R512.63

【参考文献】